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Objective. In a recent observational study, we
found that the risk of serious infection following anti–
tumor necrosis factor  (anti-TNF) therapy in pa-
tients with rheumatoid arthritis (RA) was not impor-
tantly increased compared with the background risk in
routinely treated RA patients with similar disease se-
verity. Observational data sets are, however, subject to a
number of important biases related to selection factors
for the timing of starting and stopping therapy. Infec-
tion risk is also likely to vary with duration of therapy.
This study was undertaken to examine the influences of
these biases and of the method of analysis on the risk of
infection.
Methods. We compared the risk of serious infec-
tion in 8,659 patients treated with anti-TNF with that
in 2,170 patients treated with traditional disease-
modifying antirheumatic drugs (DMARDs) recruited to
the British Society for Rheumatology Biologics Register.
We applied a number of statistical models in which we
varied the length of the followup period by using differ-
ent definitions of the date of discontinuation of treat-
ment and different lag periods of risk following drug
cessation.
Results. When the at-risk period was defined as
“receiving treatment”, the adjusted incidence rate ratio
comparing patients receiving anti-TNF therapy with
patients receiving DMARD therapy was 1.22 (95% con-
fidence interval [95% CI] 0.88–1.69). Limiting followup
to the first 90 days, however, revealed an adjusted
incidence rate ratio of 4.6 (95% CI 1.8–11.9). Rates of
infection were increased in the 90 days immediately
following drug discontinuation and beyond, explained
by selection factors for drug discontinuation.
Conclusion. These findings show that overall, the
way in which UK rheumatologists select patients for
starting and discontinuing anti-TNF therapy explains
our previous finding of no increase in risk. However,
there may be important increases in true risk, notably
early in the course of treatment, that would become
more evident depending on the definition of at-risk
period.
There are currently 3 anti–tumor necrosis factor
 (anti-TNF) drugs licensed for use in rheumatoid
arthritis (RA) in the UK: infliximab and adalimumab,
both monoclonal antibodies, and etanercept, a TNF
receptor fusion protein. Since TNF is involved in host
defense and tumor surveillance, there have been con-
cerns that anti-TNF therapy might lead to adverse
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2896events, particularly infection and malignancy. These are
complex issues, since RA itself increases the risk of
serious infection and certain malignancies, acting either
via the disease process or secondary to traditional
disease-modifying antirheumatic drugs (DMARDs).
The question that needs to be addressed is whether
anti-TNF therapy further increases that risk.
The long-term safety of treatment with biologic
response modifiers cannot, however, be addressed in
short-term randomized clinical trials, not only because
such trials have a limited duration, but also because they
recruit insufficient numbers of patients to detect rare
events. Large population-based registers are thus in-
creasingly being used to study drug safety (1–4).
A number of methodologic aspects of register
study design are now well-established. There must be a
comparison cohort of patients who are as similar as
possible to patients in the treatment cohort, aside from
taking the drug in question. Adverse events must be
reported in a robust manner with avoidance of reporting
bias. Information on potential confounders should be
collected and adjusted for in the analysis. There are,
however, obvious selection factors in determining which
patients start, and indeed stop, a particular therapy,
which are not necessarily captured even in intensive data
sets. Residual confounding is a major concern. In 2
recently published studies from Germany and the UK
(2,5), the infection rates observed in the anti-TNF
cohorts were very similar, but the 2 groups of investiga-
tors drew very different conclusions, the former estimat-
ing a doubling of risk and the latter no increased risk.
These conclusions highlight important differences be-
tween the 2 countries in their methods of selecting
comparison cohorts.
There are also a number of issues relating to the
method of analysis that are often ignored, but which
need to be considered when interpreting the data from
individual registers. This study examined the influence
Figure 1. Patterns of constancy of risk of infection while receiving treatment (on drug) and after
discontinuation of treatment (off drug). a, Increased risk at start of therapy. b, Constant risk with
ongoing drug exposure. c, Increasing risk with cumulative drug exposure. d, Combination of the risk
patterns shown in a–c. e, Ongoing constant risk for set lag window after discontinuation of treatment
(drug stop). f, Linear decrease in risk back to baseline. g, Nonlinear decrease in risk back to baseline.
h, Differing durations of risk windows, based on the half-life of each drug.
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tion rates following anti-TNF therapy in patients with
RA.
The first key question is whether any increase in
risk of infection is constant over time, or whether there
are specific times when the risk is higher or lower.
Plausible models of risk over time include increased risk
of an adverse event on initial exposure, constant risk
with ongoing drug exposure, or increasing risk with
cumulative exposure to the drug (Figures 1a–d). The
pattern of risk is likely to differ according to the adverse
event considered. An infusion reaction may be more
likely to occur early in the course of therapy, whereas a
malignancy may be related to cumulative drug exposure.
For any given adverse event, the overall risk pattern may
be a composite of these patterns.
It is also necessary to define an at-risk window,
that is, the period when adverse events should be
attributed to a drug. The minimum plausible at-risk
window would extend from the beginning of therapy to
the therapy discontinuation date (Figure 2a). Defining
this, however, is complex in the context of anti-TNF
therapy, given the administration schedule (with, in the
case of infliximab, for example, infusions several weeks
apart). In addition, depending on the pharmacokinetics
and pharmacodynamics of the drug, should the at-risk
window extend beyond the drug discontinuation date
(Figure 2b)? The third concern is whether a drug confers
a long-term risk beyond its period of pharmacologic
activity. In this case, an “ever taken drug” model
would be applicable (Figure 2c). In combination,
these factors can have substantial influences on the
measured risk.
Further, the risk once the patient has stopped
taking the drug may take one of many patterns (Figures
1e–h). It may remain constant, may decrease back to
baseline linearly or, more likely, decrease in a nonlinear
manner. It is possible that risk may never return to the
pretreatment baseline level.
Finally, the statistical approach to analysis of
changing risk pattern over time also needs to be consid-
ered. In the analysis of rare events, data may need to be
aggregated, or “smoothed,” to obtain a meaningful
estimate of risk over time. Interpretation of risk over
time may be affected by this smoothing process.
Without carefully considering these sources of
variability, the simple description of infection risk as x
cases per 1,000 person-years of therapy is impossible to
interpret. We used a large national observational study
to assess the impact of the various issues addressed
above on the estimated risk of infection following anti-
TNF therapy in patients with RA.
PATIENTS AND METHODS
The British Society for Rheumatology Biologics Reg-
ister (BSRBR). The BSRBR is a national prospective obser-
vational study that was established with the primary aim of
examining the medium- to long-term safety of biologic re-
sponse modifiers used in the rheumatic diseases. The method-
ology has been described in detail elsewhere (5,6). Briefly, it
consists of a cohort of patients with RA treated with anti-
TNF, and a comparison cohort of patients with active RA
who receive traditional DMARD therapy and have never
taken biologic response modifiers. The latter cohort exists in
the UK because of budgetary constraints on the prescription of
anti-TNF drugs (7). Members of the BSRBR Control Centre
Consortium are shown in Appendix A.
Data on demographic characteristics, disease severity
and duration, drug therapy, and comorbidity are collected at
baseline from both cohorts. All patients are then followed up
using 3 parallel methods. First, consultants are sent a ques-
tionnaire every 6 months, requesting details of all changes in
therapy and all adverse events that have occurred in that
period. Second, patients are sent a 6-month diary in which to
document all hospital admissions, new medications, and new
hospital referrals. Third, all patients are flagged with the UK
General Register Office, which provides the BSRBR with
information on deaths. Serious infections, reported from any
of these 3 sources, are defined as those that led to death or
hospitalization or required intravenous antibiotics.
To be included in the present study, patients had to
have been followed up for 6 months prior to July 31, 2006.
Followup time was censored at the last completed followup
prior to July 31, 2006, or the date of switching to a second
biologic response modifier (or first biologic response modifier
for the comparison cohort), or death, whichever came soonest.
In other words, patients who switched to a second or subse-
quent anti-TNF drug contributed time and adverse events
data to their first drug only.
Statistical analysis. Baseline characteristics of the
anti-TNF cohort were compared with those of the DMARD
cohort, using Wilcoxon’s rank sum tests for continuous vari-
ables and chi-square tests for categorical outcomes. Between-
drug comparisons were made using Kruskal-Wallis rank tests
for continuous variables. The incidence of serious infection
was then compared both between the anti-TNF cohort and
the comparison cohort and between individual anti-TNF
agents. Rates of serious infection per 1,000 person-years were
calculated using a large series of assumptions relating to the
issues described above. In each instance, incidence rate ratios
were calculated using Poisson regression, comparing the anti-
TNF cohort with the DMARD cohort. All analysis was
conducted using Stata, version 8.2 software (StataCorp, Col-
lege Station, TX).
RESULTS
Baseline characteristics. There were 10,755 pa-
tients included in the analysis (8,659 treated with anti-
2898 DIXON ET ALTNF and 2,170 treated with DMARDs only). Seventy-
four patients switched from the DMARD cohort to
the anti-TNF cohort and were included in both
groups. The baseline characteristics of the 2 co-
horts are shown in Table 1. The DMARD cohort
included proportionally more men, and patients in
Figure 2. Influence of the definition of the at-risk period on an infection being attributed to therapy. a, Duration of
treatment as the at-risk period. The at-risk window during which events can be attributed to the drug runs from 0 to
15 months. Serious infection A (at 14 months) is therefore attributed to the drug, but serious infections B (at 17
months) and C (at 23 months) are not. b, Duration of treatment plus a lag window of 3 months beyond discontinuation
of the drug as the at-risk period. Serious infections A and B are attributed to the drug, but serious infection C is not.
c, Start of treatment to the end of followup as the at-risk period. Serious infections A, B, and C are all attributed to
the drug. d, Date of the first missed dose as the drug discontinuation date (stop date). If the stop date is incorrectly
defined as the date of last dose given, rather than the first dose missed, event A will not be attributed to the drug.
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severe disease.
Risk of infection while receiving therapy. There
were 1,089 serious infections in total: 114 in the com-
parison cohort and 975 in the anti-TNF cohort, 737
occurring while the patients were receiving therapy.
Using the “receiving treatment” model of analysis (Fig-
ure 2a), the crude rate of serious infection was 39.2 per
1,000 person-years in the DMARD cohort and 55.5 per
1,000 person-years in the anti-TNF cohort, ranging from
50.4 to 63.0 events per 1,000 person-years in the 3 anti-
TNF drug cohorts (Table 2). For this “receiving treat-
ment” analysis, the at-risk period extended from the start
date of anti-TNF treatment to the first missed dose.
After adjustment for age, sex, disease duration
and severity, extraarticular RA, baseline steroid use,
diabetes, chronic obstructive pulmonary disease, and
smoking history, there was no significant difference in











(n  1,871) P†
Age, mean  SD years 60  12 56  12‡ 56  12 56  12 57  12 0.052
Sex, % female 72 76‡ 77 76 74 0.035
DAS28 score, mean  SD 5.0  1.4 6.6  1.0‡ 6.6  1.0 6.6  1.0 6.5  1.0 0.006
HAQ score, mean  SD 1.5  0.8 2.1  0.6‡ 2.1  0.6 2.1  0.5 2.0  0.6 0.001
Disease duration, median
(IQR) years
7 (1–15) 12 (6–19)‡ 12 (6–19) 12 (6–19) 11 (5–19) 0.009
Extraarticular RA, no. (%) 415 (19.1) 2,541 (29.3)‡ 1,123 (29.2) 896 (30.4) 522 (27.9) 0.131
Baseline steroid use, no. (%) 418 (19.3) 3,793 (43.8)‡ 1,784 (46.4) 1,342 (45.6) 663 (35.4) 0.016
Diabetes, no. (%) 132 (6.1) 470 (5.4) 230 (6.0) 134 (4.6) 106 (5.7) 0.031
COPD/asthma, no. (%) 416 (19.2) 1,130 (13.1)‡ 536 (13.9) 361 (12.3) 233 (12.5) 0.082
Smoking history, no. (%)
Current smoker 537 (25) 1,886 (22)§ 797 (21) 650 (22) 436 (23) 0.045¶
Former smoker 849 (39) 3,298 (38) 1,454 (38) 1,107 (38) 733 (39)
Never smoked 767 (35) 3,431 (40) 1,568 (41) 1,169 (40) 690 (37)
* Seventy-four patients switched from the cohort treated with disease-modifying antirheumatic drugs (DMARDs) to the cohort treated with
anti–tumor necrosis factor  (anti-TNF) drugs and were counted in both groups. Smoking history was available for 2,153 patients treated with
DMARDs and 8,615 patients treated with anti-TNF drugs. DAS28  Disease Activity Score in 28 joints; HAQ  Health Assessment
Questionnaire; IQR  interquartile range; RA  rheumatoid arthritis; COPD  chronic obstructive pulmonary disease.
† Across 3 anti-TNF drugs.
‡ P  0.001 versus DMARD-treated patients.
§ P for trend  0.001.
¶ P for trend.











Model A, receiving treatment
Person-years 2,908 6,021 5,034 2,221 13,277
No. of infections 114 308 317 112 737
Rate per 1,000 person-years (95% CI) 39.2 (32.3–47.1) 51.2 (45.6–57.2) 63.0 (56.2–70.3) 50.4 (41.5–60.7) 55.5 (51.7–59.5)
Adjusted incidence rate ratio (95% CI)† Referent 1.15 (0.82–1.61) 1.28 (0.91–1.81) 1.17 (0.81–1.69) 1.22 (0.88–1.69)
Model B, duration of treatment plus 90-day lag window
Person-years 2,908 6,274 5,226 2,323 13,823
No. of infections 114 361 354 127 842
Rate per 1,000 person-years (95% CI) 39.2 (32.3–47.1) 57.5 (51.8–63.8) 67.7 (60.9–75.2) 54.7 (45.6–65.0) 60.9 (57.0–65.0)
Adjusted incidence rate ratio (95% CI)† Referent 1.26 (0.91–1.74) 1.35 (0.97–1.89) 1.24 (0.87–1.78) 1.30 (0.93–1.78)
Model C, ever received treatment
Person-years 2,908 6,998 5,874 2,548 15,420
No. of infections 114 432 405 138 975
Rate per 1,000 person-years (95% CI) 39.2 (32.3–47.1) 61.7 (56.0–67.8) 68.9 (62.4–76.0) 54.2 (45.5–64.0) 63.2 (59.4–67.2)
Adjusted incidence rate ratio (95% CI)† Referent 1.34 (0.97–1.86) 1.41 (1.02–1.97) 1.25 (0.88–1.77) 1.35 (0.99–1.85)
* 95% CI  95% confidence interval (see Table 1 for other definitions).
† Adjusted for age, sex, disease duration and severity, extraarticular rheumatoid arthritis, baseline steroid use, diabetes, chronic obstructive
pulmonary disease, and smoking history.
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and the comparison cohort. These results are consistent
with the findings published in our previous report on
serious infection rates, with followup to September 2005
(5). In this observational study, the treating rheumatol-
ogist was aware of the patient’s therapy at the time of
infection, possibly leading to a lower threshold for
admission into the anti-TNF cohort. However, such a
bias does not explain these findings.
Constancy of risk. A plot of the cumulative
incidence of serious infections while receiving treatment
(Figure 3a) showed that at any given point in time, it was
more likely that patients in the anti-TNF cohorts had a
serious infection compared with patients in the compar-
ison cohort. This does not necessarily mean that the
absolute risk was higher at all time points in the anti-
TNF cohorts. In order to explore this, and to evaluate
the change in risk over time (as in Figure 1), a plot of the
slope of the curves in Figure 3a, or hazard plot, was
constructed. This showed a marked increase in hazard in
the anti-TNF cohorts, peaking at 6 months, but
declining over time (Figure 3b).
To further explore a possible early risk of infec-
tion (Figure 1a), the rates of serious infections were
analyzed with followup censored at 90 days after the
start of anti-TNF therapy (or 90 days after registration
date in the DMARD cohort) (Table 3). The adjusted
incidence rate ratios for the 3 anti-TNF drugs com-
pared with the DMARD cohort showed an 4-fold or
greater risk of serious infection in the first 90 days.
These ratios were much higher than the incidence rate
ratios seen for the entire followup period (Table 2).
This result is biologically plausible, suggesting an
increased early risk of infection in the anti-TNF cohort.
However, as shown in Figure 3b, the increased incidence
rate ratios in the first 90 days appeared to be driven not
only by the elevated crude rates of infection in the
anti-TNF cohorts, but also by the low early crude rates
in the DMARD cohort. Both cohorts, but particularly
the anti-TNF group, were screened before initiation of
treatment, to avoid inclusion of patients who had an
imminent serious infection. However, such a difference
between the groups in prescreening would bias against
an increased risk in the anti-TNF group and does not
explain this early increased risk.
Selection factors also apply after recruitment. If a
patient in the anti-TNF cohort developed an incident
serious infection, the physician made an active treatment
decision about whether therapy should be continued
once the acute infection had resolved. Some patients
were considered to be at high risk of a future infection
and did not resume therapy. Therefore, the anti-TNF
cohort in a “receiving treatment” analysis had a progres-
sively lower risk of infection over time because of the
selective exclusion of high-risk patients. This may ex-
plain the gradual reduction in risk from the 6-month
time point onward.
Because of clinical decisions influencing the ob-
served pattern of risk, it is very difficult to ascertain the
true pattern of risk, and a possible real increase in
cumulative risk may be hidden by the selection factors
described above. Thus, over the period of observation,
the decisions made in clinical practice in conjunction
with the underlying serious infection risk of the drugs
Figure 3. Cumulative incidence of infections (a) and risk of serious
infection (b), by drug. The y-axis shows the hazard, or risk, of serious
infection. ETA  etanercept; INF  infliximab; ADA  adalimumab;
DMARD  disease-modifying antirheumatic drug.
INFECTION FOLLOWING ANTI-TNF THERAPY IN RA 2901did not lead to an increasing risk of serious infections
over time. This is not the same as concluding that these
agents do not lead to an increase in infection risk.
Exploration of the fluctuation of serious infection risk in
between doses of the drugs is made virtually impossible
by these same factors.
Influence of choice of date of discontinuation of
treatment. Within the BSRBR, stop dates for all 3
anti-TNF drugs are based on clinical records. An
accurate definition of the stop date is particularly im-
portant for infliximab, given the prolonged interval
between infusions. In 90% of records, the given stop
date for infliximab was the last infusion date. However,
an adverse event caused by the drug (apart from an
infusion reaction) is unlikely to occur at the time of an
infusion, and thus the stop date should be the first
missed dose, rather than the last dose given. Indeed,
such events are often the reason for discontinuing the
drug. If the date of the last dose given were used as the
stop date, events which followed the last infusion (event
A in Figure 2d) would not be attributable to the drug in
the analysis, grossly underestimating the event rate.
Defining the stop date as the last dose given for inflix-
imab leads to an infection incidence rate of 49.0 per
1,000 person-years, much lower than the 63.0 per 1,000
person-years shown above. Thus, for all BSRBR analy-
ses, including the “receiving treatment” analysis (Table
2), the stop date was defined as the first missed dose.
Influence of lag window. Once treatment is dis-
continued, the risk associated with the drug may not
immediately return to the predrug baseline. To address
this, the at-risk window was extended for an arbitrary
period beyond the first missed dose. Thus, in the follow-
ing analysis, events occurring in the 90 days after the
stop date (first missed dose) for each of the 3 drugs were
considered attributable to that drug, as in Figure 2b.
The crude rates of serious infection in this ana-
lysis ranged from 54.7 to 67.7 per 1,000 person-years for
the 3 anti-TNF drugs (Table 2). These rates were
higher than those found when the analysis was restricted
to the “receiving treatment” period for all 3 drugs (Table
2). In fact, the rate of serious infection was higher in the
90-day window after drug discontinuation than during
the treatment period. The rates per 1,000 person-years
(95% confidence intervals [95% CIs]) in the 3 cohorts in
this 90-day window after discontinuation of anti-TNF
therapy were 202 (153–256) for etanercept, 193 (139–
256) for infliximab, and 147 (85–231) for adalimumab.
The incidence rate ratios (95% CIs) in the first 90 days
after discontinuation of treatment compared with the
rates while receiving treatment were 3.3 (2.4–4.5) for
etanercept, 2.8 (1.9–4.1) for infliximab, and 2.5 (1.3–4.8)
for adalimumab.
These findings are counterintuitive, since the risk
of serious infection would be expected to decrease once
anti-TNF treatment was discontinued. This could be
explained by a rebound in disease activity after discon-
tinuation of the drugs. However, the major reason for
the increased risk in this 90-day window became clear on
reviewing the individual case histories: the infection was
causally related to the reason for discontinuing the drug.
In the majority of cases, the reason was an adverse
event. The subsequent infection may have been either a
direct or an indirect consequence of the initial adverse
event, e.g., an aspiration pneumonia following a stroke,
or an opportunistic infection following chemotherapy
for a malignancy. In other cases (for example, prior to
surgery), discontinuation of treatment was planned. This
event is associated with its own inherent increased risk of
infection, elevating the risk in the time period after
discontinuation. Further, the drug may have been dis-
continued because of symptoms of a serious infection,
though the infection was only diagnosed some time later.
This last scenario would also have resulted in an under-
estimation of the rate of serious infections in the anti-
TNF cohort in a “receiving treatment” analysis, and











Person-years 532 917 723 451 2,091
No. of infections 13 55 69 27 151
Rate per 1,000 person-years
(95% CI)
24.4 (13.1–41.4) 60.0 (45.5–77.4) 95.4 (75.0–119.2) 59.9 (39.8–85.9) 72.2 (61.5–84.2)
Adjusted incidence rate ratio
(95% CI)†
Referent 4.1 (1.5–10.8) 5.6 (2.1–15.1) 3.9 (1.3–11.2) 4.6 (1.8–11.9)
* 95% CI  95% confidence interval (see Table 1 for other definitions).
† Adjusted for age, sex, disease duration and severity, extraarticular rheumatoid arthritis, baseline steroid use, diabetes, chronic obstructive
pulmonary disease, and smoking history.
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reflection of the true rate.
The influence of these selection variables on
serious infection during the lag window makes it very
difficult to explore the true pattern of infection risk for
the anti-TNF drugs once discontinued (Figures 1e–h).
Such considerations also make it hard to compare the
differing patterns between the drugs. For example, is
there a longer lag window of risk for infliximab com-
pared with etanercept, given its longer half-life? While it
is possible to calculate the rates for lag windows set
differently for the 3 drugs based on multiples of their
half-lives, these rates are very difficult to interpret given
the presence of other factors, such as the reason for drug
discontinuation.
Continued risk after discontinuation of treat-
ment. An important question to address in relation to
anti-TNF drugs is, assuming there is an increased risk
of certain adverse events while taking the drug (and
during a lag phase after discontinuation), whether that
risk returns to baseline or is persistent. If it is persistent,
for how long does the risk continue? Such an ongoing
risk would be particularly relevant for adverse events
such as malignancy, though less so for serious infections.
It would be expected that any effect that anti-TNF
drugs have on susceptibility to infection would subside
within months of discontinuing the drug. One way to
explore this is to look at the serious infection rate for the
entire followup period, regardless of the date of drug
discontinuation (Figure 2c). Using this model, the rates
of serious infection for the 3 anti-TNF drugs were 61.7
per 1,000 person-years for etanercept, 68.9 per 1,000
person-years for infliximab, and 54.2 per 1,000 person-
years for adalimumab (Table 2). These rates were also
higher than those found using either the “receiving
treatment” or the “duration of treatment plus 90-day lag
window” analyses, as discussed above.
Again, these results seem counterintuitive. As
with the lag phase analysis, the reason for drug discon-
tinuation may influence the rate of subsequent infection,
but this influence should decline with time. For
example, if the treatment is stopped for planned
surgery, the postoperative infection risk declines with
time, and infection risk should return to presurgical
levels.
The reason for the increased risk in this model
may relate to the active treatment decisions made in an
observational study. For patients who have a serious
infection while receiving anti-TNF therapy, clinicians
will decide whether treatment should be resumed, based
on their opinion of further infection risk. Thus, there is
a “healthy drug continuers” or “depletion of suscep-
tibles” effect, and restricting analysis to those who
continue the drug selectively retains those at the lowest
risk.
DISCUSSION
In a recently published report (5) we showed that
the overall risk of severe infection was not increased
following anti-TNF therapy. In this extended analysis it
is clear that there are several influences that make it very
difficult to generate a robust answer to this superficially
simple question. The risk of infection attributable to
anti-TNF therapy measured in an observational study
cannot be adequately summarized as a single estimate.
Large national registers have the capacity to reveal some
of the patterns of adverse events that might otherwise be
hidden behind such a point estimate.
It is important to be specific about aspects such as
time period of interest during therapy, the choice of stop
date, what allowance should be made for continuing
pharmacologic action, and how to evaluate risk follow-
ing these periods. Although standardization of analytical
approach will help in comparing the findings of different
studies, selection factors for both starting, and as we
have shown, discontinuing therapy may seriously com-
promise interpretation.
In the future, defining stop dates will become
even more difficult. Rituximab, an anti-CD20 B cell–
depleting drug, is now licensed for the treatment of RA
(8). It is given in 2 infusions 2 weeks apart, with its
effects lasting for 6–12 months. When can a patient be
considered to be receiving or not receiving this treat-
ment?
Despite these concerns, use of a consistent meth-
odologic approach in all population registers is essential.
However, it is equally important to avoid making over-
simplistic conclusions about the infection risk conferred
by these drugs.
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APPENDIX A: BSRBR CONTROL CENTRE
CONSORTIUM
The BSRBR Control Centre Consortium consists of the
following institutions (all in the UK): Antrim Area Hospital, Antrim
(Nicola Maiden); Cannock Chase Hospital, Cannock Chase (Tom
Price); Christchurch Hospital, Christchurch (Neil Hopkinson); Derby-
shire Royal Infirmary, Derby (Sheila O’Reilly); Dewsbury and District
Hospital, Dewsbury (Lesley Hordon); Freeman Hospital, Newcastle-
upon-Tyne (Ian Griffiths); Gartnavel General Hospital, Glasgow
(Duncan Porter); Glasgow Royal Infirmary, Glasgow (Hilary Capell);
Haywood Hospital, Stoke-on-Trent (Andy Hassell); Hope Hospital,
Salford (Romela Benitha); King’s College Hospital, London (Ernest
Choy); Kings Mill Centre, Sutton-In-Ashfield (David Walsh); Leeds
General Infirmary, Leeds (Paul Emery); Macclesfield District General
Hospital, Macclesfield (Susan Knight); Manchester Royal Infirmary,
Manchester (Ian Bruce); Musgrave Park Hospital, Belfast (Allister
Taggart); Norfolk and Norwich University Hospital, Norwich (David
Scott); Poole General Hospital, Poole (Paul Thompson); Queen
Alexandra Hospital, Portsmouth (Fiona McCrae); Royal Glamorgan
Hospital, Glamorgan (Rhian Goodfellow); Russells Hall Hospital,
Dudley (George Kitas); Selly Oak Hospital, Selly Oak (Ronald Jubb);
St. Helens Hospital, St. Helens (Rikki Abernethy); and Withington
Hospital, Manchester (Paul Sanders).
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